Sign up
Pharma Capital

Creso Pharma and Virbac to launch hemp‐based animal health products

The recession‐resistant animal health market is estimated to be worth US$30bn.
A dog and cat
The company’s products are designed for companion animals such as dogs

Creso Pharma (ASX:CPH) has signed an agreement with Virbac, a global pharmaceutical animal health company, to launch its hemp‐based complementary animal feed products in Switzerland.

Creso has developed and will manufacture the products and Virbac will launch, market and promote the products to veterinarians and pet owners.

The agreement starts from 1 September, 2017 and remains in effect for at least 3 years, in Switzerland and Lichtenstein.

READ: Creso Pharma’s partner imports medicinal cannabis products into Australia

Virbac is a pharmaceutical animal health company with a presence in over 100 countries and ranks as the 7th largest pharmaceutical veterinary company worldwide.

Creso is innovating in the development, manufacturing and commercialisation of nutraceutical products for human and animal health using hemp‐based, full‐plant extracts.

The company’s anibidiol®1.25 and anibidiol® 2.5 are designed for companion animals such as dogs and cats and come in proprietary granule formulations.

They address stress and behavioural problems, chronic pain (mainly arthritis), and age‐related ailments in ageing animals.

READ: Creso Pharma to raise funds after share price rally

The anibidiol® product range address the need of non‐pharmaceutical therapeutic approaches which are natural and well tolerated by the animals.

The recession‐resistant worldwide animal health market is estimated to be worth US$30bn and is projected to continue to show rapid growth.

Around 57% of households own a pet, and 33% own a dog.

Interestingly, 41% of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).



Register here to be notified of future CPH Company articles
View full CPH profile

Creso Pharma Ltd Timeline

View All

Related Articles

Antibiotics
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.